AMARIN CORP PLC\UK Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
AMARIN CORP PLC\UK (AMRN) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $2.06 per share as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-03-02
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $2.06.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $2.70.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $3.35.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $5.83.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2025-12-31 | $2.06 10-K · filed 2026-03-02 |
| 2024-12-31 | $2.70 10-K · filed 2025-03-12 |
| 2023-12-31 | $3.35 10-K · filed 2024-02-29 |
| 2022-12-31 | $5.83 10-K · filed 2023-03-01 |
| 2021-12-31 | $7.30 10-K · filed 2022-03-01 |
| 2020-12-31 | $7.91 10-K · filed 2021-02-25 |
| 2019-12-31 | $6.34 10-K · filed 2020-02-25 |
| 2018-12-31 | $4.27 10-K · filed 2019-02-27 |
| 2017-12-31 | $3.27 10-K · filed 2018-02-27 |
| 2016-12-31 | $3.41 10-K · filed 2017-03-01 |
| 2015-12-31 | $4.04 10-K · filed 2016-02-25 |
| 2014-12-31 | $6.03 10-K · filed 2015-03-03 |
| 2013-12-31 | $6.57 10-K · filed 2014-02-27 |
| 2012-12-31 | $7.26 10-K · filed 2013-02-28 |
| 2011-12-31 | $5.32 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |